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Abstract 
Strategies targeting cross-talk between immunosuppressive renal dendritic cells (DCs) and T regulatory 
cells (Tregs) may be effective in treating cisplatin (CDDP)-induced acute kidney injury (AKI). Galectin 3 
(Gal-3), expressed on renal DCs, is known as a crucial regulator of immune response in the kidneys. In 
this study, we investigated the role of Gal-3 for DCs-mediated expansion of Tregs in the attenuation of 
CDDP-induced AKI. 
Methods: AKI was induced in CDDP-treated wild type (WT) C57BL/6 and Gal-3 deficient (Gal-3-/-) 
mice. Biochemical, histological analysis, enzyme-linked immunosorbent assay (ELISA), 
immunohistochemistry, real-time PCR, magnetic cell sorting, flow cytometry and intracellular staining of 
renal-infiltrated immune cells were used to determine the differences between CDDP-treated WT and 
Gal-3-/- mice. Newly synthesized selective inhibitor of Gal-3 (Davanat) was used for pharmacological 
inhibition of Gal-3. Recombinant Gal-3 was used to demonstrate the effects of exogenously administered 
soluble Gal-3 on AKI progression. Pam3CSK4 was used for activation of Toll-like receptor (TLR)-2 in 
DCs. Cyclophosphamide or anti-CD25 antibody were used for the depletion of Tregs. 1-Methyl 
Tryptophan (1-MT) was used for pharmacological inhibition of Indoleamine 2,3-dioxygenase-1 (IDO1) in 
TLR-2-primed DCs which were afterwards used in passive transfer experiments.  
Results: CDDP-induced nephrotoxicity was significantly more aggravated in Gal-3-/- mice. Significantly 
reduced number of immunosuppressive TLR-2 and IDO1-expressing renal DCs, lower serum levels of 
KYN, decreased presence of IL-10-producing Tregs and significantly higher number of inflammatory 
IFN-γ and IL-17-producing neutrophils, Th1 and Th17 cells were observed in the CDDP-injured kidneys 
of Gal-3-/- mice. Pharmacological inhibitor of Gal-3 aggravated CDDP-induced AKI in WT animals while 
recombinant Gal-3 attenuated renal injury and inflammation in CDDP-treated Gal-3-/- mice. 
CDDP-induced apoptosis, driven by Bax and caspase-3, was aggravated in Gal-3-/- animals and in WT mice 
that received Gal-3 inhibitor (CDDP+Davanat-treated mice). Recombinant Gal-3 managed to completely 
attenuate CDDP-induced apoptosis in CDDP-injured kidneys of Gal-3-/- mice. Genetic deletion as well as 
pharmacological inhibition of Gal-3 in renal DCs remarkably reduced TLR-2-dependent activation of 
IDO1/KYN pathway in these cells diminishing their capacity to prevent transdifferentiation of Tregs in 
inflammatory Th1 and Th17 cells. Additionally, Tregs generated by Gal-3 deficient DCs were not able to 
suppress production of IFN-γ and IL-17 in activated neutrophils. TLR-2-primed DCs significantly 









Gal-3 on TLR-2-primed DCs was crucially important for their capacity to enhance nephroprotective and 
immunosuppressive properties of Tregs. Adoptive transfer of TLR-2-primed WTDCs significantly 
expanded Tregs in the kidneys of CDDP-treated WT and Gal-3-/- recipients resulting in the suppression 
of IFN-γ and IL-17-driven inflammation and alleviation of AKI. Importantly, this phenomenon was not 
observed in CDDP-treated WT and Gal-3-/- recipients of TLR-2-primed Gal-3-/-DCs. Gal-3-dependent 
nephroprotective and immunosuppressive effects of renal DCs was due to the IDO1-induced expansion 
of renal Tregs since either inhibition of IDO1 activity in TLR-2-primed DCs or depletion of Tregs 
completely diminished DCs-mediated attenuation of CDDP-induced AKI.  
Conclusions: Gal-3 protects from CDDP-induced AKI by promoting TLR-2-dependent activation of 
IDO1/KYN pathway in renal DCs resulting in increased expansion of immunosuppressive Tregs in injured 
kidneys. Activation of Gal-3:TLR-2:IDO1 pathway in renal DCs should be further explored as new 
therapeutic approach for DC-based immunosuppression of inflammatory renal diseases. 
Key words: cisplatin-induced acute kidney injury, Galectin 3, renal dendritic cells, Toll-like receptor-2, 
Indoleamine 2,3-dioxygenase-1 
Introduction 
Cisplatin (cis-diamminedichloroplatinum II, 
CDDP) is one of the most effective chemotherapeutic 
agents [1]. However, its clinical use is limited due to 
the severe side effects, including acute kidney injury 
(AKI) which has been observed in 30-40% of 
CDDP-treated patients [1]. During glomerular 
filtration and tubular secretion, CDDP accumulates in 
the proximal tubular epithelial cells (PTECs) which 
absorb molecules from primary urine and are mainly 
exposed to urinary excreted CDDP [1]. CDDP induces 
extensive production of free radicals and reactive 
oxygen species (ROS) in PTECs resulting in the 
development of oxidative stress which accelerates 
formation of advanced glycosylation end products 
(AGEs) and exacerbates AKI [1]. Additionally, 
damage-associated molecular patterns (DAMPs), 
released from CDDP-injured PTECs, activate toll-like 
receptor (TLR)-4 on renal macrophages resulting in 
the production of inflammatory chemokines and 
cytokines which enable massive recruitment of 
circulating interferon gamma (IFN-γ) and interleukin 
(IL)-17-producing neutrophils and T cells in injured 
kidneys leading to the aggravation of AKI [2]. In 
contrast to TLR-4, TLR-2 protects against 
CDDP-caused nephrotoxicity [3]. Activation of TLR-2 
promotes generation of tolerogenic and 
immunosuppressive phenotype in renal dendritic 
cells (DCs), which are considered as the main renal 
residential immune cells with nephroprotective 
function [4]. Through the production of 
anti-inflammatory IL-10, renal DCs suppress 
detrimental IFN-γ and IL-17-driven immune response 
in injured kidneys and attenuate CDDP-induced 
inflammation [5-6]. Nevertheless, inhibition of IL-10 
production only partially reduces nephroprotective 
effects of renal DCs [6], suggesting that other 
DC-derived immunosuppressive mediators also 
contribute to the DC-dependent attenuation of 
CDDP-induced AKI.  
Upon activation, tissue resident tolerogenic DCs 
express Indoleamine 2,3-dioxygenase 1 (IDO1) which 
metabolizes tryptophan to Kynurenine (KYN) [7]. 
DC-derived KYN promotes expansion of Tregs in 
inflamed colon, lungs, brain, synovia, myocardium, 
skin and liver resulting in attenuated inflammation 
and enhanced regeneration of injured tissues [8]. T 
regulatory cells (Tregs) are immunosuppressive cells 
which, 6 hours after CDDP-induced damage of 
PTECs, migrate in injured kidneys and in juxtacrine 
and paracrine manner, suppress IFN-γ and 
IL-17-producing neutrophils and T cells resulting in 
alleviation of AKI [9-10]. Although DC-derived IDO1 
represents possible molecular target for attenuation of 
CDDP-induced AKI, molecular mechanism which 
regulates IDO1-mediated cross-talk between renal 
DCs and Tregs in CDDP-injured kidneys is still 
unknown.  
Considerable interest has recently arisen in the 
intriguing immunomodulatory properties of Galectin 
3 (Gal-3), a member of β-galactoside-binding lectins, 
which regulates numerous biological processes in the 
kidneys including migration, proliferation and 
activation of resident and renal-infiltrated immune 
cells [11]. A large number of studies reported different 
(pro-or anti-inflammatory) role of Gal-3 in the 
development and progression of organ specific 
inflammatory diseases [12-17]. Interestingly, use of 
different disease-causing agents may induce opposite 
Gal-3-dependent effects in the same tissue [18-20], 
suggesting that Gal-3-dependent effects are 
determined by etiological agents and inflammatory 
microenvironment of injured tissue. In persistent or 
repetitive kidney injury, overexpression of Gal-3 
promotes apoptosis and collagen I synthesis in renal 
cells enhancing transition of acute to chronic 
inflammation and fibrosis [11]. Accordingly, elevated 
plasma levels of Gal-3 have been observed in patients 
with chronic kidney diseases and inhibition of Gal-3 





prevented development of renal fibrosis [21-25]. 
Oppositely, Galectin-3 has an important 
nephroprotective role in response to ischemic and 
nephrotoxic AKI [26-27]. Gal-3 serves as a receptor for 
AGEs in the kidneys and is crucially important for 
protection towards AGE-dependent renal injury [28]. 
Accordingly, genetic deletion of Gal-3 impairs uptake 
and removal of AGEs resulting in aggravation of 
AGE-induced glomerular injury and diabetic 
nephropathy [27]. Having in mind that Gal-3 is 
constitutively expressed on renal DCs and that 
increased levels of AGEs, induced by CDDP, promote 
generation of tolerogenic phenotype in renal DCs [29], 
we analyzed the role of Gal-3 for DC-dependent 
alleviation of CDDP-induced AKI. By using 
complementary in vitro and in vivo approaches we 
demonstrated that genetic deletion as well as 
pharmacological inhibition of Gal-3 significantly 
impaired capacity of TLR-2-primed renal DCs to 
express IDO1 and produce immunosuppressive KYN 
which resulted in significantly reduced presence of 
renal-infiltrated Tregs and notably aggravated 
CDDP-induced AKI. Therefore, we propose that Gal-3 
protects from CDDP-caused nephrotoxicity by 
promoting TLR-2-dependent activation of 
IDO1/KYN pathway in renal DCs resulting in 
increased expansion of immunosuppressive Tregs in 
injured kidneys. 
Material and Methods 
Animals. Male, 6-8-week-old wild type (WT) 
and Gal-3-/- C57BL/6 mice were used for the 
induction of CDDP-induced AKI. Breeding pairs of 
Gal-3-/- and WT C57BL/6 mice of the same substrain 
were initially obtained from Dr. Daniel Hsu 
(University of California, Davis, USA) [30] and 
maintained in animal facilities of the Faculty of 
Medical Sciences, University of Kragujevac, Serbia. 
All animals received humane care and all experiments 
were approved by and conducted in accordance with, 
the Guidelines of the Animal Ethics Committee of the 
Faculty of Medical Sciences, University of Kragujevac, 
Serbia. Mice were housed in a temperature-controlled 
environment with a 12-h light-dark cycle and were 
administered standard laboratory chow and water ad 
libitum.  
Induction of AKI. To generate CDDP-induced 
AKI, WT and Gal-3-/- mice were injected with a single, 
intraperitoneal (i.p) dose of CDDP (16 mg/kg body 
weight). After mouse euthanasia (72 h after CDDP 
treatment), both kidneys were excised and blood 
samples were drawn from the inferior vena cava, as 
previously described [31]. 
Administration of recombinant Gal-3 (rGal-3). 
In order to evaluate the effects of rGal-3 in attenuation 
of CDDP-induced AKI, Gal-3-/- mice received single 
intravenous injection of rGal-3 (5 μg; Peprotech, 
Rocky Hill, NJ, United States), 24 h before CDDP 
administration [20]. Gal-3-/- animals from control 
group received only saline. 
Pharmacological inhibition of Gal-3. Gal-3 
inhibitor (Davanat; kindly provided by Professor 
Klyosov and Professor Traber from Galectin 
Therapeutics Inc., Newton, MA) was intraperitoneally 
injected in CDDP-treated WT animals (100 μg/day), 
for three consecutive days before CDDP 
administration [17]. WT animals from control group 
received only saline. 
Evaluation of CDDP-induced AKI. 
CDDP-induced AKI was evaluated by biochemical 
and histological analysis, as previously described [31]. 
Biochemical analysis. Serum levels of urea and 
creatinine were determined to assess the renal 
function. After blood collection, serum levels of these 
toxicity markers were measured immediately using 
assay kits and blood chemistry analyzer, according to 
the manufacturer’s instructions [31].  
Histopathological Analysis. Kidney tissue was 
fixed in 10% buffered formalin, embedded in paraffin 
and cut at 5 μm thickness. Sections were stained with 
Hematoxylin and Eosin (H&E) and examined in a 
blinded manner. Histological sections were scored 
using a semi-quantitative scale designed to assess 
AKI-associated tubular injury (tubular epithelial cell 
loss, necrosis, tubular epithelial simplification, 
intratubular debris, and casts) by a pathologist 
blinded to the experimental groups (using >5 random 
fields/section, 4-5 mice/group). Tubule injury scores 
(ranging between 0 and 4) were based on the 
percentage of tubules affected as follows: 0 ≤ 10%, 
1 = 10–25%, 2 = 26–50%, 3 = 51–75%, and 4 ≥ 75%, as 
previously described [31]. 
Immunohistochemistry. In order to assess 
expression of AGEs, Galectin-3 and TLR2 in the 
kidneys of WT and Gal-3-/- mice, 
immunohistochemical (IHC) analysis was performed. 
Formalin-Fixed Paraffin-Embedded (FFPE) kidney 
tissue sections were incubated with rabbit anti-mouse 
AGE antibody (ab23722, Abcam Inc., Cambridge, MA, 
USA), rabbit anti-mouse Galectin 3 antibody (ab2785, 
Abcam Inc., Cambridge, MA, USA) and rabbit 
anti-mouse TLR2 antibody (ab213676, Abcam Inc., 
Cambridge, MA, USA) overnight at room 
temperature. Immunoreactivity was visualized by 
rabbit-specific conjugate (Expose Rb-Specific 
HRP/DAB Detection IHC Kit; Abcam) according to 
the manufacturer's instructions. Sections were 
photomicrographed with a digital camera mounted 
on light microscope (Olympus BX51), digitized, and 
analyzed Analysis was performed on 10 fields per 





section at 40x magnification. Results are presented as 
mean count of positive stained cells per field [16].  
Isolation of Renal-Infiltrated Immune Cells. 
Isolation of immune cells from the kidneys was 
conducted as previously described [31]. Briefly, the 
kidneys were cut into small pieces (1-2 mm in 
dimension) using a regular metal shaping blade and 
placed into the collagenase solution for 30-45 min in 
the incubator at 37 °C. The cells were filtered through 
a 70 μm nylon cell strainer and then, cells were 
pelleted by centrifuging 10 min at 400×g, at 4 °C. 
Pellet was resuspended in 4 mL of 40% Percoll 
solution and gently overlaid onto 4 mL of 80% Percoll 
solution. Slight whitish translucent layers of cells 
were collected from the interface of the two Percoll 
phases after centrifugation at 1500×g for 30 min. 
These cells were then collected and pelleted by 
centrifuging 10 min at 400×g, at 4 °C. Cells were 
resuspended in 1 mL of Dulbecco's Modified Eagle 
Medium (DMEM), and the total number of cells was 
determined by using trypan blue exclusion on a 
hemocytometer [31]. 
Flow cytometry of renal-infiltrated immune 
cells. For flow cytometry, 1×106 of renal-infiltrated 
cells were incubated with anti-mouse CD45, Gr-1, 
F4/80, CD4, CD11c, CD80, CD86, MHC-II, TLR-2, 
Gal-3 monoclonal antibodies conjugated with 
fluorescein isothiocyanate (FITC), phycoerythrin (PE), 
peridinin chlorophyll protein (PerCP), or 
allophycocyanin (APC) (all from BD Biosciences, San 
Jose, CA, USA) following the manufacturer's 
instructions. Immune cells derived from the kidneys 
were concomitantly stained for the intracellular 
content of IFN-γ, IL-17, IL-4, IL-10, IL-12, T-bet, 
RORγt, STAT3, IDO1, IL-23 and forkhead box P3 
(FoxP3) by using the fixation/permeabilization kit 
and anti-mouse monoclonal antibodies conjugated 
with fluorescein isothiocyanate (FITC), phycoerythrin 
(PE), peridinin chlorophyll protein (PerCP), and 
allophycocyanin (APC) (BD Bioscience). For 
intracellular cytokine staining, cells were stimulated 
with 50 ng/mL Phorbol 12-myristate-13-acetate 
(PMA) and 500 ng/mL Ionomycin for 5 h, and 
GolgiStop (BD Biosciences) was added. Cells were 
fixed in Cytofix/Cytoperm, permeated with 0.1% 
saponin, and stained with fluorescent Abs. Flow 
cytometry was conducted on a BD Biosciences 
FACSCalibur and data were analyzed by Flowing 
Software analysis program. 
Isolation and TLR-2-priming of DCs. DCs were 
isolated from the kidneys of healthy WT and Gal-3-/- 
mice by magnetic cell sorting. Single-cell suspensions 
of renal-infiltrated mononuclear cells were labelled 
with CD11c MicroBeads (Miltenyi Biotec). The 
labelled cells were subsequently positively selected 
using MACS Column (Miltenyi Biotec) and MACS 
Separator (Miltenyi Biotec), as previously described 
[32]. Isolated renal DCs (3×105/ mL) were primed 
with TLR-2 agonist Pam3CSK4 (300 ng/mL) for 24 h. 
As a naive control, renal DCs were cultured in the 
absence of TLR-2 ligand for 24h [32]. 
Pharmacological inhibition of Gal-3 in DCs. 
For pharmacological inhibition of Gal-3, unprimed 
and TLR-2-primed renal DCs were cultured in the 
presence of selective Gal-3 inhibitor (Davanat, 0.015 
mg/mL) for 24 h, according to previously published 
protocol [33]. 
Pharmacological inhibition of IDO1 activity in 
DCs. IDO1 was inhibited in TLR-primed renal DCs 
(WTDCsPam3CSK4+1-MT) and Gal-3-/-DCs 
(Gal-3-/-DCsPam3CSK4+1-MT) by using 1-methyl 
tryptophan (1-MT; 2 mM; Sigma-Aldrich, Munich, 
Germany), as previously described [34].  
Transfer of TLR-2 primed DCs in 
CDDP-treated animals. For transfer-based 
experiments, TLR-2-primed DCs, isolated from the 
kidneys of untreated WT and Gal‐3-/- mice 
(WTDCsPam3CSK4 and Gal‐3-/-DCsPam3CSK4), were 
intravenously injected (5×105cells/mouse) in 
CDDP-treated WT recipients (WTWTDCsPam3CSK4 and 
WTGal‐3-/-DCsPam3CSK4) or Gal‐3-/- recipients (Gal‐
3-/-WTDCsPam3CSK4 and Gal‐3-/-Gal‐3-/-DCsPam3CSK4) two days 
prior CDDP administration [35]. The extent of renal 
injury was evaluated as described above. 
Measurement of cytokines. The commercial 
enzyme-linked immunosorbent assay (ELISA) sets 
(R&D Systems, Minneapolis, MN) were used to 
determine the concentration of IL-12, IL-1β, IL-6, 
IL-23, IL-17, IFN-γ and IL-10 in serum samples of 
saline and CDDP-treated animals, according to the 
manufacturer’s instructions [31]. 
Determination of IDO1 activity. IDO1 activity 
in serums samples of saline and CDDP-treated mice 
as well as in supernatants of unprimed and 
TLR-2-primed WTDCs, Gal-3-/-DCs and WTDCsDavanat 
was determined by spectrophotometric measuring of 
KYN [32]. 
Isolation of neutrophils. Neutrophils were 
isolated from healthy WT animals by magnetic cell 
sorting (Neutrophil Biotin-Antibody Cocktail, 
Miltenyi Biotec, Bergisch Gladbach, Germany), 
according to manufacturer's instructions. Isolated 
neutrophils were stimulated by lipopolysaccharide 
(LPS, 100 ng/mL) for 18 h and used in the co-culture 
experiments with Tregs [36]. 
Isolation of Tregs. Tregs were isolated from the 
population of renal-infiltrated mononuclear cells by 
magnetic cell sorting (Tregs isolation kit, Miltenyi 
Biotec, Bergisch Gladbach, Germany), according to 
manufacturer's instructions [37].  





Contact-independent co-culture of 
TLR-2-primed DCs and Tregs. Tregs were 
co-cultured in the presence of WT DCsPam3CSK4, 
WTDCPam3CSK4+Davanat or Gal-3-/-DCsPam3CSK4, as 
previously described [38]. Tregs and DCs were 
cultured physically separated using a 0.4 µm porous 
transwell system (Corning Incorporated, Life 
Sciences, France). Tregs were placed in the lower 
chamber of 24 well plate and cultured in the presence 
of WTDCsPam3CSK4, WTDCPam3CSK4+Davanat or 
Gal-3-/-DCsPam3CSK which were seeded in the transwell 
inserts, and ratio between DCs and Tregs was 1:10.  
After 48h of culture, non-primed Tregs or Tregs 
primed with WTDCsPam3CSK4, WTDCPam3CSK4+Davanat or 
Gal-3-/-DCsPam3CSK were collected and used for 
co-culture experiments with neutrophils, ELISA 
assay, flow cytometry analysis and intracellular 
staining of FoxP3, IFN-γ, IL-17 and IL-10 or frozen at 
-80 °C until gene expression were measured by 
real-time PCR. Non-primed Tregs or Tregs primed 
with WTDCsPam3CSK4, WTDCPam3CSK4+Davanat or 
Gal-3-/-DCsPam3CSK (2x106 cells/ well) were collected, 
seeded at 24 well plate, cultured for additional 24h in 
fresh DMEM medium. Supernatants were collected 
and IFN-γ, IL-17 and IL-10 were determined by ELISA 
sets (R&D Systems, Minneapolis, MN), according to 
the manufacturer’s instructions [31]. 
Co-culture of Tregs and neutrophils. 
Non-primed Tregs as well as Tregs, previously 
primed by WTDCsPam3CSK4, WTDCPam3CSK4+Davanat or 
Gal-3-/-DCsPam3CSK4, were co-cultured with 
LPS-activated neutrophils, as previously described 
[36]. DC-primed Tregs and neutrophils were cultured 
physically separated using a 0.4 µm porous transwell 
system (Corning Incorporated, Life Sciences, France). 
Neutrophils were placed in the lower chamber of 24 
well plate and cultured in the presence of non-primed 
Tregs or Tregs primed with WTDCsPam3CSK4, 
WTDCPam3CSK4+Davanat or Gal-3-/-DCsPam3CSK which were 
seeded in the transwell inserts, and ratio between 
neutrophils and Tregs was 10:1. After 48 h, the 
expression of IFN-γ, IL-17 and IL-10 in neutrophils 
was evaluated by real time PCR analysis. Neutrophils 
were collected, seeded at 24 well plate (1x106 cells/ 
well), cultured for additional 24 h in fresh DMEM 
medium. Supernatants were collected and IFN-γ, 
IL-17 and IL-10 were determined by ELISA sets (R&D 
Systems, Minneapolis, MN), according to the 
manufacturer’s instructions [31]. 
RNA isolation and real‐time PCR analysis. 
Total RNA from kidneys, Tregs or neutrophils was 
extracted using TRIzol reagent (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer's 
instructions. Total RNA (2 μg) was reversely 
transcribed to cDNA using High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster 
City, California, USA). qRT-PCR was performed 
using Power SYBR MasterMix (Applied Biosystems) 
and miRNA-specific primers for IFN-γ, IL-17, IL-10, 
FoxP3, T-bet, RORγT, Bax, Bcl-2, caspase-3 and β-actin 
as a housekeeping gene. qPCR reactions were 
initiated with a 10 min incubation time at 95 °C 
followed by 40 cycles of 95 °C for 15 s and 60 °C for 60 
s in a Mastercycler ep realplex (Eppendorf, Hamburg, 
Germany). Relative expression of genes was 
calculated according to the formula 2-(Ct-Ctactin), 
where Ct is the cycle threshold of the gene of interest 
and Ctactin is the cycle threshold value of the 
housekeeping gene (β-actin) [38]. 
Transfer of Tregs. Tregs were 
fluorescence-labeled using pre-incubation with 
carboxyfluorescein diacetate succin-imidyl ester 
(CFSE; Molecular Probes, Thermo FisherScientific, 
Stockholm, Sweden) according to the manufacturer’s 
instructions. For transfer experiments non-primed 
Tregs, Tregs primed with WTDCPam3CSK4, 
WTDCPam3CSK4+Davanat or Gal-3-/- DCPam3CSK4 (1x106 
Tregs/ mouse) were intravenously injected in 
CDDP-treated animals, 18 h before induction of AKI. 
Depletion of Treg cells. For the depletion of 
Tregs, CDDP-treated WTWTDCPam3CSK4 and 
Gal-3-/-WTDCPam3CSK4 mice received either 
cyclophosphamide (CY, Galenika A.D., Belgrade, 
Serbia) 3 days before CDDP administration, at a dose 
of 10 mg/kg which was reported to selectively 
deplete Tregs but not DCs [19] or anti-CD25 (P61) 
monoclonal antibody (250 μg per mouse; eBioscience; 
San Diego, CA, USA) [39]. 
Isolation and transfer of macrophages in 
CDDP-treated mice. Macrophages, isolated from 
healthy WT and Gal-3-/- mice, were stimulated with 
Pam3CSK4 (300 ng/mL; WTMϕPam3CSK4 and 
Gal-3-/-MϕPam3CSK4) and injected via the tail vein 
(1x106/ mouse) 2 h before induction of AKI, as 
previously suggested [40].  
Statistics. Data were expressed as the Mean ± 
standard error of the mean (SEM) for each group. 
Results were analyzed by Student’s t test and 
Pearson’s or Spearman’s correlation coefficient. 
Statistical analyses were performed using SPSS 23.0 
for Windows software (SPSS Inc., Chicago, IL). The 
difference was considered significant when p<0.05. 
Results 
Genetic deletion of Gal-3 significantly 
aggravates AKI and inflammation 
CDDP caused significant renal dysfunction in 
WT and Gal-3-/- mice as reflected by a marked 
elevation of serum urea and creatinine (Figure 1A). 





Importantly, CDDP-induced nephrotoxicity was 
significantly more aggravated in Gal-3-/- mice. Serum 
levels of urea (p<0.05, Figure 1A left panel) and 
creatinine (p<0.01, Fig.1A right panel) were 
significantly higher in CDDP-treated Gal-3-/- mice 
when compared to similarly treated WT animals. An 
aggravated deterioration of kidney function, observed 
in CDDP-treated Gal-3-/- mice, was confirmed by 
histological score (Figure 1B). Kidneys obtained from 
control animals had normal histology (Figure 1C, 
upper panels). CDDP treatment induced more severe 
tubular epithelial cell injury, tubular dilation, and 
intra-tubular cast formation in Gal-3-/- mice compared 
to WT animals (Figure 1C, lower panels), which 
resulted in significantly higher histological score 
(p<0.01, Figure 1B) in CDDP-treated Gal-3-/- mice, 
confirming that genetic deletion of Gal-3 remarkably 
aggravated AKI. 
It is well known that CDDP induces apoptosis of 
proximal tubular epithelial cells [41] and that Gal-3 
has anti-apoptotic function in epithelial cells [42]. 
Accordingly, significantly higher expression of 
pro-apoptotic Bax and caspase 3 and significantly 
lower expression of anti-apoptotic Bcl-2 were noticed 
in the CDDP-injured kidneys of Gal-3-/- mice 
compared to their WT counterparts (p<0.05 for Bax 




Figure 1. Genetic deletion of Gal-3 significantly aggravates CDDP-induced AKI, apoptosis and inflammation. WT and Gal-3-/- mice were injected with a single, 
intraperitoneal dose of CDDP (16 mg/kg body weight). Acute renal failure was aggravated in Gal-3-/- mice 72 h after CDDP treatment, as evidenced by increased concentration 
of urea and creatinine (A), higher histological score (B) and more severe tubular epithelial cell injury, tubular dilation, and intra-tubular cast formation in the cortex of 
CDDP-injured kidneys (C). Genetic deletion of Gal-3 significantly increased apoptosis in CDDP-injured kidneys as evidenced by increased expression of Bax and caspase-3 and 
decreased expression of Bcl-2 (D). CDDP treatment significantly up-regulated expression of Gal-3 (E) and TLR-2 (F). Gal-3 deletion significantly attenuated CDDP-induced 
increase of TLR-2 in the kidneys and significantly increased expression of AGEs (G). Significantly increased serum levels of Th1 and Th17-promoting inflammatory cytokines 
(IL-12, IL-1β, IL-6 and IL-23) (H) and decreased levels of immunosuppressive IL-10 (I) and KYN (J) were observed in CDDP-treated Gal-3-/- animals. Data from two individual 
experiments with 8 mice per group are shown as Mean ± SEM; *p<0.05, **p<0.01,***p<0.001. 





TLR-2 is constitutively expressed in the kidneys 
and protects against CDDP-induced AKI by 
promoting autophagy in tubular epithelial cells [43]. 
Since autophagy delays apoptosis of tubular epithelial 
cells [44], we analyzed whether Gal-3 deficiency 
affected TLR-2 expression in CDDP-injured kidneys. 
Immunohistochemical analysis revealed that 
expression of both Gal-3 (p<0.05; Figure 1E) and 
TLR-2 (p<0.01; Figure 1F) were significantly increased 
in the kidneys upon CDDP administration. 
Importantly, genetic deletion of Gal-3 significantly 
reduced expression of TLR-2 in CDDP-treated mice 
(p<0.05; Figure 1F), suggesting that Gal-3 has 
important role in TLR-2-dependent nephroprotection. 
Additionally, Gal-3 deficiency resulted with 
reduced uptake and enhanced accumulation of AGEs 
in the injured kidneys of CDDP-treated Gal-3-/- mice 
(p<0.01; Figure 1G) which corresponded to the 
aggravated renal injury (Fig.1A-C), apoptosis (Figure 
1D) and inflammation (Figure 1H-J). Significantly 
higher concentrations of pro-inflammatory cytokines 
which are necessary for the induction of Th1 (IL-12 
(p<0.001)) and Th17 immune response (IL-1β 
(p<0.001), IL-6 (p<0.01), IL-23 (p<0.05)) were found in 
serum samples of CDDP-treated Gal-3-/- mice when 
compared to similarly treated WT mice (Figure 1H). 
Additionally, significantly lower serum levels of 
anti-inflammatory and immunosuppressive 
mediators (IL-10 (p<0.001, Figure 1I)) and kynurenine 
(KYN, p<0.01, Figure 1J) were observed in 
CDDP-treated Gal-3-/- mice, suggesting that Gal-3 has 
important immuno-regulatory role in CDDP-induced 
kidney injury and inflammation. 
Pharmacological inhibitor of Gal-3 aggravated 
CDDP-induced AKI in WT animals while 
recombinant Gal-3 attenuated renal injury and 
inflammation in CDDP-treated Gal-3-/- mice 
In order to confirm protective role of Gal-3 in 
CDDP-caused AKI, we analyzed the effects of Gal-3 
inhibitor (Davanat) and recombinant Gal-3 (rGal-3) on 
the development of CDDP-induced acute renal failure 
in WT and Gal-3-/- animals. As it is shown in Figure 
S1, Davanat inhibited expression of Gal-3 in saline 
and CDDP-injured kidneys. Importantly, Davanat 
significantly enhanced CDDP-induced AKI in WT 
mice, as evidenced by elevated serum levels of urea 
and creatinine (p<0.001 for urea and p<0.01 for 
creatinine; Figure 2A) and significantly increased 
histological score (p<0.01; Figure 2B). Histological 
analysis revealed more severe tubular epithelial cell 
injury in the kidneys of CDDP+Davanat-treated WT 
mice (Figure 2C). Additionally, expression of 
pro-apoptotic Bax and caspase-3 were significantly 
higher and expression of anti-apoptotic Bcl-2 was 
significantly lower in the kidneys of 
CDDP+Davanat-treated WT mice compared to 
CDDP-only-treated WT animals (p<0.01; Figure 2D), 
confirming important anti-apoptotic role of Gal-3 in 
CDDP-induced AKI. 
Complementary to these findings are results 
obtained after administration of rGal-3 in 
CDDP-treated Gal-3-/- mice (Figure 2E-H). Serum 
levels of urea and creatinine (p<0.01; Figure 2E), 
histological score (p<0.001; Figure 2F), injury of 
tubular epithelial cells (Figure 2G) and expression of 
pro-apoptotic Bax and caspase-3 (p<0.05; Figure 2H) 
were significantly lower, while expression of 
anti-apoptotic Bcl-2 was significantly higher (p<0.01; 
Figure 2H) in the kidneys of CDDP-treated Gal-3-/- 
mice that received rGal-3.  
Gal-3 deficiency affected phenotype and 
function of renal-infiltrated neutrophils and 
macrophages in CDDP-treated animals  
An increase in serum concentration of 
inflammatory cytokines (IL-1β and IL-6) is associated 
with a massive influx of neutrophils in CDDP-injured 
kidneys [45]. Since we noticed significantly higher 
serum levels of IL-1β and IL-6 in CDDP-treated 
Gal-3-/- mice (Figure 1H), we compared phenotype 
and function of renal-infiltrated neutrophils between 
these two experimental groups (Figure 3A-E). CDDP 
induced massive influx of neutrophils in kidneys of 
WT and Gal-3-/- mice without significant difference in 
their total number (Figure 3A). However, intracellular 
staining revealed that significantly higher number of 
inflammatory, IFN-γ and IL-17-producing neutrophils 
infiltrated the kidneys of CDDP-treated Gal-3-/- mice 
(Figure 3B-C, p<0.05). Additionally, reduced presence 
of nephroprotective IL-4 (Figure 3D, p<0.01) and 
IL-10-producing neutrophils (Figure 3E, p<0.05) 
[46-48] were found in CDDP-injured kidneys of 
Gal-3-/-mice, suggesting that Gal-3 deficiency affected 
phenotype and function of renal-infiltrated 
neutrophils of CDDP-treated animals. 
Gal-3 regulates secretion of cytokines and 
chemokines in macrophages playing important role in 
modulation of organ-specific and systemic 
inflammatory diseases [49]. In line with previously 
published studies [50, 51], we noticed positive 
correlation between the extent of AKI and total 
number of renal-infiltrated macrophages (Figure 2F). 
Importantly, aggravated acute renal failure, observed 
in CDDP-injured Gal-3-/- mice compared to similarly 
treated WT animals (Figure 1), corresponded to the 
notably higher presence of renal-infiltrated F4/80+ 
macrophages (Figure 3G, P<0.001).  







Figure 2. Davanat significantly aggravated CDDP-induced AKI in WT animals while rGal-3 attenuated renal injury and inflammation in CDDP-treated 
Gal-3-/- mice. Davanat was intraperitoneally injected in CDDP-treated WT animals (100 μg/day), for three consecutive days before CDDP administration (16 mg/kg body 
weight). Gal-3-/- mice received single intravenous injection of rGal-3 (5 μg), 24 hours before CDDP administration. Davanat significantly enhanced CDDP-induced AKI in WT 
mice, as evidenced by elevated serum levels of urea and creatinine (A) and significantly increased histological score (B). Histological analysis revealed more severe tubular 
epithelial cell injury in the cortex of the kidneys of CDDP+Davanat-treated WT mice (C). Expression of pro-apoptotic Bax and caspase-3 were significantly higher and expression 
of anti-apoptotic Bcl-2 was significantly lower in the kidneys of CDDP+Davanat-treated WT mice compared to CDDP-only-treated WT animals (D).Serum levels of urea and 
creatinine (E), histological score (F), injury of tubular epithelial cells (G) and expression of pro-apoptotic Bax and caspase-3 (H) were significantly lower, while expression of 
anti-apoptotic Bcl-2 was significantly higher (H) in the kidneys of CDDP+rGal-3-treated Gal-3-/- mice. Individual data points with Mean, obtained in one experiment with 6 mice 
per group; *p<0.05, **p<0.01,***p<0.001. 






Figure 3. Gal-3 deficiency promoted development of inflammatory phenotype in renal-infiltrated neutrophils and macrophages. Bar graphs (left panels) and 
representative density plots obtained by flow cytometry analysis and intracellular staining of renal-infiltrated neutrophils and macrophages derived from saline or CDDP-treated 
WT and Gal-3-/- mice, 72 h after CDDP administration (16 mg/kg body weight). There was no significant difference in total number of CD45+Gr-1+neutrophils (gated as 
CD45+Gr-1+cells in population of renal infiltrated cells) between CDDP-injured kidneys of WT and Gal-3-/- animals (A). Significantly higher number of inflammatory, IFN-γ (B) 
and IL-17-producing neutrophils (C), and notably lower total number of IL-4-producing (D) and IL-10 producing neutrophils (E) were noticed in the kidneys of CDDP-treated 
Gal-3-/- mice. Representative density plots show percentages of IFN-y-, IL-17-, IL-4- and IL-10-producing neutrophils (Fig.2B-E), gated in the population of CD45+Gr-1+ renal 
infiltrated cells. Strong positive correlation was observed between histological score and total number of renal-infiltrated macrophages (F) which was found in significantly higher 
number in the kidneys of CDDP-treated Gal-3-/- mice (G). Representative density plots showing higher percentage of macrophages in renal infiltrated cells of CDDP-treated 
Gal-3-/- mice compared to similarly treated WT animals (G, right panel). Macrophages are determined as F4/80+cells, gated in population of CD45+CD11c- renal infiltrated cells. 





Significantly higher number of IL-12-producing M1 macrophages (H, left panel), but lower number of IL-10-producing M2 macrophages (I, right panel) were noticed in the kidneys 
of CDDP-treated Gal-3-/- mice. Positive correlation was observed between histological score and total number of IL-12-producing renal-infiltrated M1 macrophages (H, middle 
panel) and negative correlation was noticed between histological score and total number of IL-10-producing renal-infiltrated M2 macrophages (I, middle panel). Representative 
density plots show percentages of IL-12-producing (H, right panel) and IL-10-producing macrophages (I, right panel), gated in the population of F4/80+ renal infiltrated cells of 
CDDP-treated WT and Gal-3-/- animals. Data from two individual experiments with 8 mice per group are shown as Mean ± SEM; *p<0.05, **p<0.01,***p<0.001. 
 
It is well known that CDDP treatment induces 
enhanced expression of IL-12 in inflammatory M1 
macrophages resulting in the progression of AKI and, 
at the same time, suppresses generation of 
alternatively activated and renoprotective, 
IL-10-producing M2 macrophages [52]. In line with 
these findings, we noticed positive correlation 
between percentage of M1 macrophages and the 
extent of renal injury in CDDP-treated WT and 
Gal-3-/- mice (Figure 3H, left panel) and negative 
correlation between percentage of renal-infiltrated M2 
macrophages and histological score of CDDP-treated 
WT and Gal-3 deficient animals (Figure 3I, left panel). 
Importantly, significantly higher number of 
inflammatory, IL-12-producing macrophages (p<0.01; 
Figure 3H right panel) and remarkably reduced 
presence of nephroprotective, IL-10-producing M2 
macrophages (p<0.05; Figure 3I right panel) in the 
kidneys of CDDP-treated Gal-3-/- mice, suggesting 
that Gal-3 had important role in regulation of 
CDDP-induced polarization of renal macrophages. 
Since Gal-3 needs association with TLR-2 for 
modulation of macrophage function [53], we 
investigated whether genetic deletion of Gal-3 alters 
capacity of TLR-2-primed macrophages to modulate 
CDDP-induced nephrotoxicity. Serum levels of urea 
and creatinine (Figure S2A) and histological score 
(Figure S2B) were not significantly different between 
CDDP-treated WT recipients of TLR-2-primed WT 
and Gal-3-/-macrophages, suggesting that increased 
infiltration of M1 macrophages and decreased 
presence of M2 macrophages in damaged kidneys of 
CDDP-treated Gal-3-/- mice was just a reflection of the 
severity of AKI rather than its cause and that 
aggravated CDDP-induced AKI, seen in Gal-3-/- 
animals, developed due to the dysfunction of other 
Gal-3-expressing regulatory immune cells with 
nephroprotective function.  
Gal-3 deficiency significantly increased total 
number of inflammatory Th1 and Th17 cells 
and remarkably reduced presence of 
regulatory T cells in CDDP-injured kidneys  
Having in mind that crosstalk between 
renal-infiltrated neutrophils and Th17 cells as well as 
interaction between renal macrophages and Th1 cells 
have been implicated in the pathogenesis of AKI [54, 
55], we analyzed phenotype and function of effector 
CD4+T cells in the CDDP-injured kidneys of WT and 
Gal-3-/- mice (Figure 4A-H). As shown in Figure 4A, 
significantly higher number of CD4+T cells was 
present in the kidneys of CDDP-treated Gal-3-/- mice 
(p<0.01). Intracellular staining revealed that notably 
higher number of inflammatory T-bet expressing and 
IFN-γ producing Th1 cells (Figure 4B-C, p<0.01) as 
well as RORγT expressing and IL-17-producing Th17 
cells (Figure 4D-E, p<0.01) infiltrated injured kidneys 
of CDDP-treated Gal-3-/- animals than their WT 
counterparts.  
In line with these data were results obtained by 
real-time PCR gene expression analysis (Figure 4I). 
There was significantly higher mRNA expression of 
T-bet, IFN-γ, RORγT and IL-17 in the kidneys of 
CDDP-treated Gal-3-/- mice compared to similarly 
treated WT animals (p<0.05 for IFN-γ, IL-17 and 
IL-10; p<0.01 for T-bet, RORγT; Figure 4I). 
Additionally, Gal-3 deficiency significantly 
attenuated mRNA expression of FoxP3 and IL-10 
(p<0.05 for IL-10; p<0.01 for FoxP3; Figure 4I) and 
remarkably reduced presence of renoprotective and 
immunosuppressive IL-10-producing, FoxP3 and 
STAT3-expressing regulatory T cells in CDDP-injured 
kidneys (Figure 4F-H, p<0.01) [56], indicating the 
important role of Gal-3 for generation of Tregs in 
CDDP-induced AKI.  
In order to determine whether genetic deletion 
of Gal-3 affected migratory capacity and 
immunosuppressive properties of Tregs, 
CSFE-labeled WT and Gal-3-/-Tregs were 
intravenously injected in CDDP-treated WT mice and 
their number and function were evaluated by flow 
cytometry (Figure 5 and Figure S3). As it is shown in 
Figure 5A similar number of CSFE-labeled WT and 
Gal-3-/-Tregs were detected in the kidneys of 
CDDP-treated WT recipients. Engrafted WT and 
Gal-3-/- Tregs managed to significantly attenuate 
CDDP-induced AKI, as evidenced by significantly 
lower serum levels of urea and creatinine (p<0.01; 
Figure 5B) and reduced histological score (p<0.01; 
Figure 5C). Cellular-make-up of CDDP-injured 
kidneys revealed that WT and Gal-3-/- Tregs 
significantly reduced total number of IFN-γ and 
IL-17-producing neutrophils (p<0.01; Figure 5D-E) 
and CD4+ T cells (p<0.01; Figure 5F-G). Importantly, 
there was no significant difference in 
nephroprotective effects and immunosuppressive 
capacity of WT and Gal-3-/-Tregs, suggesting that 
genetic deletion of Gal-3 did not directly affect 
migratory capacity and immunosuppressive 
properties of Tregs. 






Figure 4. Gal-3 deficiency significantly increased total number of inflammatory Th1 and Th17 cells and reduced presence of regulatory T cells in 
CDDP-injured kidneys. Bar graphs (left panels) and representative density plots obtained by flow cytometry analysis and intracellular staining of renal-infiltrated CD4+T cells 
derived from saline or CDDP-treated WT and Gal-3-/- mice, 72 h after CDDP administration (16 mg/kg body weight). Gal-3 deficiency resulted with increased presence of 
CD4+T cells in the CDDP-injured kidneys (A, left panel). Representative density plots showing CD4+ T lymphocytes, gated as CD4+ cells in population of renal infiltrated cells 
(A, right panel). Significantly higher total number of T-bet-expressing (B) and IFN-γ-producing (C) CD4+Th1 cells and RORγT-expressing (D) and IL-17-producing (E) CD4+Th17 





cells, but reduced presence of immunosuppressive IL-10-producing CD4+T cells (F), CD4+FoxP3+ Tregs (G) and STAT-3-expressing Treg (H) were noticed in the kidneys of 
CDDP-treated Gal-3-/- mice. Representative density plots showing percentages of T-bet-expressing, IFN-γ-producing, RORγT-expressing, IL-17-producing, IL-10-producing, 
FoxP3-expressing cells, gated in the population of CD4+Tcells (B-G, right panels) and percentage of STAT-3-expressing cells in gated population of CD4+FoxP3+ Tregs (H, right 
panel), isolated from the kidneys of CDDP-treated WT and Gal-3-/- mice, 72h after CDDP administration. Real-time PCR gene analysis showing significantly higher mRNA 
expression of T-bet, IFN-γ, RORγT, IL-17 and lower mRNA expression of FoxP3 in CDDP-injured kidneys of Gal-3-/- mice compared to similarly treated WT animals (I). Data 
from two individual experiments with 8 mice per group are shown as Mean ± SEM; *p<0.05, **p<0.01,***p<0.001. 
 
Figure 5. Genetic deletion of Gal-3 did not alter migratory capacity and immunosuppressive properties of Tregs. Tregs were fluorescence-labeled using 
pre-incubation with carboxyfluorescein diacetate succin-imidyl ester (CFSE). CSFE-labeled WT and Gal-3-/-Tregs were intravenously injected (1x106 Tregs/mouse) in 
CDDP-treated WT mice and their number and function were evaluated by flow cytometry. Representative dotplots showing similar percentage and total number of CSFE-labeled 
WT and Gal-3-/-Tregs in the kidneys of CDDP-treated WT recipients. Engrafted WT and Gal-3-/- Tregs managed to significantly attenuate CDDP-induced AKI, as evidenced by 
significantly lower serum levels of urea and creatinine (B) and reduced histological score (C), but there was no significant difference in the extent of AKI between CDDP-treated 
mice that received WT and Gal-3-/-Tregs, which was confirmed by representative kidney tissue sections. WT and Gal-3-/- Tregs significantly reduced total number of IFN-γ and 
IL-17-producing neutrophils (5D-E) and CD4+ T cells (5F-G) but there was no significant difference in the total number of these cells between CDDP-treated mice that received 
WT and Gal-3-/-Tregs. Individual data points with Mean, obtained in one experiment with 6 mice per group; *p<0.05, **p<0.01,***p<0.001. 
 
Target disruption of Gal-3 significantly 
attenuated immunosuppressive capacity of 
renal-infiltrated DCs and enhanced their 
potential to generate detrimental Th1 and 
Th17 immune response in CDDP-injured 
kidneys 
In order to determine whether Gal-3 deficiency 
altered function of renal-infiltrated DCs which guide 
T cell-driven immune response in CDDP-induced 
nephrotoxicity [6], we analyzed phenotype of 
renal-infiltrated F4/80-CD11c+DCs in WT and 
Gal-3-/- mice. F4/80-CD11c+DCs were present in 
significantly higher number in kidneys of 
CDDP-treated Gal-3-/- mice (Figure 6A, p<0.05). 
Intracellular staining revealed that target disruption 
of Gal-3 significantly attenuated capacity of 
renal-infiltrated DCs to produce renoprotective and 
immunosuppressive IL-10 (Figure 6B, p<0.05) and 
IDO1 (Figure 6C, p<0.01) and enhanced their capacity 





to generate detrimental Th1 and Th17 immune 
response in CDDP-injured kidneys (Figure 6D-H). 
Significantly higher number of DCs that expressed 
co-stimulatory CD80 (Figure 6D, p<0.05) and CD86 
molecules (Figure 6E, p<0.01), major 
histocompatibility class II (I-A) molecule (Figure 6F, 
p<0.05), IL-12-producing (Figure 6G, p<0.05) as well 
as IL-23-producing DCs (Figure 6H, p<0.05) were 
noticed in the kidneys of CDDP-treated Gal-3-/- mice 
compared to WT animals.  
Gal-3 is required for TLR-2-dependent 
activation of IDO1/KYN pathway in renal DCs 
and consequent generation of 
immunosuppressive Tregs 
It is well known that CDDP treatment induces 
increased expression of renoprotective TLR-2 in 
injured kidneys [3] and that DCs suppress Th1 and 
Th17 driven inflammation by promoting expansion of 
Tregs in IDO1/KYN-dependent manner [57]. 
Accordingly, we evaluated the importance of Gal-3 
for TLR2-dependent immunosuppressive function of 
renal DCs in CDDP-induced AKI. Firstly, we noticed 
strong positive correlation between percentages of 
Gal-3+CD11c+DCs and TLR-2+CD11c+DCs in the 
kidneys (Figure 7A; r=0.733). Gal-3 was expressed on 
the membrane of the majority of 
TLR-2+F4/80-CD11c+renal DCs (Figure 7B). 
CDDP-provoked expression of TLR-2 on renal DCs 
was remarkably reduced in Gal-3-/- mice (p<0.001; 
Figure 7C), indicating importance of Gal-3 for 
TLR-2-dependent signaling in renal DCs. In line with 
these findings, there was strong positive correlation 
between percentages of IDO1+CD11c+DCs and 
TLR-2+CD11c+DCs in the kidneys (Figure 7D; 
r=0.721). IDO1 was expressed in the majority of 
TLR-2+F4/80-CD11c+renal DCs (Figure 7E). 
Intracellular staining revealed that majority of TLR-2 
and Gal-3-expressing renal DCs express IDO1 and 
most of TLR-2+Gal-3+IDO1+DCs express 
immunosuppressive IL-10 (Figure 7F). 
In order to confirm importance of Gal-3 for 
TLR-2-dependent activation of immunosuppressive 
IDO1/KYN pathway in DCs, we analyzed the 
difference in KYN production between TLR-2-primed 
WTDCs (WTDCsPam3CSK4) and WTDCsPam3CSK4 that 
were cultured in the presence of selective Gal-3 
inhibitor-Davanat (WTDCsPam3CSK4+Davanat) (Figure 
7G). Activation of TLR-2 significantly enhanced 
production of immunosuppressive KYN in renal DCs 
(Figure 7G). Importantly, genetic deletion as well as 
pharmacological inhibition of Gal-3, remarkably 
reduced TLR-2-dependent secretion of KYN in 
WTDCs (Figure 7G). Significantly lower 
concentrations of KYN were measured in 
supernatants of Gal-3-/-DCsPam3CSK4 and 
WTDCsPAM3CSK4+Davanat compared to WTDCsPam3CSK4 
(Figure 7G, p<0.05).  
Genetic deletion as well as pharmacological 
inhibition of Gal-3 in WTDCsPam3CSK4 diminished their 
capacity to maintain immunosuppressive phenotype 
of Tregs and to prevent trans-differentiation of Tregs 
in Th1 or Th17 cells (Figure 7H-J). Decreased 
expression and production of anti-inflammatory IL-10 
(p<0.01) and increased expression and production of 
inflammatory IFN-γ (p<0.01) and IL-17 (p<0.01) were 
noticed in CD4+CD25+FoxP3+Tregs which had been 
cultured with Gal-3-/-DCsPam3CSK4 or WT 
DCsPAM3CSK4+Davanat compared to Tregs that were 
cultured alone or with WTDCsPam3CSK4 (Figure 7H-J; 
Figure S4). 
Additionally, Tregs generated by 
Gal-3-/-DCsPam3CSK4 or WTDCsPam3CSK4+Davanat were not 
able to optimally suppress expression and production 
of IFN-γ and IL-17 (p<0.05 for IFN-γ, p<0.01 for IL-17; 
Figure 7K-L) or to induce enhanced expression and 
production of IL-10 (p<0.01, Figure 7K-L) in activated 
neutrophils, indicating the importance of Gal-3 for 
DC-driven regulation of cross-talk between Tregs and 
neutrophils. 
Intravenous injection of TLR-2 primed 
WTDCs significantly attenuated 
CDDP-induced AKI by promoting expansion of 
immunosuppressive Tregs in 
IDO1/KYN-dependent manner  
In order to demonstrate crucial role of Gal-3 for 
DCsPam3CSK4-dependent modulation of CDDP-induced 
AKI, we injected WTDCsPam3CSK4 or 
Gal-3-/-DCsPam3CSK4 in CDDP-treated WT or Gal-3-/- 
recipients. Transfer of WTDCsPam3CSK4 attenuated 
CDDP-injured AKI and inflammation in 
CDDP-treated WT recipients (WTWTDCsPam3CSK4), as 
evidenced by notably lower serum levels of urea 
(Figure 8A, p<0.05), creatinine (Figure 8B, p<0.05) and 
inflammatory cytokines (IL-12, IL-1β, IL-6, IL-17, 
IFN-γ, p<0.05, Fig.8E left panel). Significantly reduced 
histological score (Figure 8C) and preserved renal 
architecture (Figure 8D), seen in CDDP-treated 
WTWTDCsPam3CSK4 mice, were accompanied by elevated 
serum levels of immunosuppressive IL-10 (Figure 8E 
middle panel, p<0.05) and KYN (Figure 8E right 
panel, p<0.01), remarkable expansion of 
renal-infiltrated CD4+FoxP3+Tregs (Figure 8F, 
p<0.001), IL-10-producing neutrophils (Figure 8G, 
p<0.01) and CD4+ T cells (Figure 8H, p<0.05) and 
significantly lower number of IFN-γ and 
IL-17-producing neutrophils (Figure 8I-J, p<0.05) and 
CD4+ T lymphocytes (Figure 8K-L, p<0.05).  






Figure 6. Target disruption of Gal-3 significantly attenuated immunosuppressive capacity of renal-infiltrated DCs and enhanced their potential to 
generate detrimental Th1 and Th17 immune response in CDDP-injured kidneys. Bar graphs (left panels) and representative density plots obtained by flow cytometry 
analysis and intracellular staining of renal-infiltrated DCs derived from saline or CDDP-treated WT and Gal-3-/- mice, 72 h after CDDP administration (16 mg/kg body weight). 
Gal-3 deficiency resulted with increased presence of F4/80-CD11+DCs in the CDDP-injured kidneys (A). Representative density plots showing higher percentage of DCs in renal 
infiltrated cells of CDDP-treated Gal-3-/- mice compared to similarly treated WT animals (A, right panel). DCs are determined as F4/80- CD11c+ renal infiltrated cells. 





Significantly lower number of IL-10-producing (B) and IDO1-expressing F4/80-CD11+DCs, but remarkably higher number of CD80-expressing (D), CD86-expressing (E), 
I-A-expressing (F), IL-12-producing (G) and IL-23-producing F4/80-CD11+DCs were noticed in the kidneys of CDDP-treated Gal-3-/- mice. Representative density plots showing 
percentages of IL-10-producing, IDO1-, CD80-, CD86-, I-A-expressing, IL-12 and IL-23-producing cells, gated in the population of F4/80-CD11c+ renal DCs isolated from the 
kidneys of CDDP-treated WT and Gal-3-/- mice, 72 h after CDDP injection (B-G, right panels). Data from two individual experiments with 8 mice per group are shown as Mean 
± SEM; *p<0.05, **p<0.01. 
 
Figure 7. Gal-3 is required for TLR-2-dependent activation of IDO1/KYN pathway in renal DCs and consequent generation of immunosuppressive Tregs. 
There was strong positive correlation between percentages of Gal-3+CD11c+DCs and TLR-2+CD11c+DCs in the kidneys (A). Representative flow cytometry dot plots showing 
expression of Gal-3 in TLR-2+ cells previously gated in the population of F4/80-CD11c+ renal DCs (B). Significantly lower number of TLR-2-expressing CD11c+DCs was 
observed in the kidneys of CDDP-treated Gal-3-/- mice compared to CDDP-treated WT animals, 72 h after CDDP injection (16 mg/kg body weight). There was strong positive 
correlation between percentages of IDO1+CD11c+DCs and TLR-2+CD11c+DCs in the kidneys (D). Representative flow cytometry dot plots showing expression of IDO1 in 
TLR-2+ cells previously gated in the population of F4/80-CD11c+ renal DCs (E). Representative dot plots showing that majority of TLR-2+Gal-3+IDO1+DCs express IL-10 (F). 
Significantly lower concentrations of KYN were noticed in supernatants of Gal-3-/-DCsPam3CSK4 and WTDCsPAM3CSK4+Davanat compared to WTDCsPam3CSK4 (G). Real-time PCR gene 
analysis (H), ELISA (I) and flow cytometry (J) results showing expression and production of inflammatory IFN-γ, IL-17, and anti-inflammatory IL-10 in Tregs (H, J) and appropriate 
supernatants (I) before and after culturing with WTDCsPam3CSK4, Gal-3-/-DCsPam3CSK4 or WT DCsPAM3CSK4+Davanat in contact-independent manner within transwell system (ratio 
between DCs and Tregs was 1:10). Real-time PCR gene analysis (K) and ELISA (L) results showing expression and production of inflammatory IFN-γ, IL-17 and anti-inflammatory 
IL-10 in LPS-activated neutrophils that were cultured with Tregs previously stimulated by WTDCsPam3CSK4, Gal-3-/-DCsPam3CSK4 or WT DCsPAM3CSK4+Davanat. Transwell systems were 
used to separate neutrophils and Tregs and ratio between neutrophils and Tregs was 10:1. Data from two individual experiments with 8 mice per group are shown as Mean ± 
SEM; *p<0.05, **p<0.01;***p<0.001. 
 
On the contrary, single intravenous injection of 
Gal-3-/-DCsPam3CSK4 notably aggravated CDDP- 
induced AKI in WT recipients (WTGal-3-/-DCsPam3CSK4), as 
evidenced by significantly increased serum levels of 
urea (Figure 8A, p<0.01), creatinine (Figure 8B, 
p<0.05), histological score (Figure 8C, p<0.05) and 
massive destruction of proximal tubules (Figure 8D). 
As it is shown in Figure 8E, consistent with the 





deterioration of kidney function, significantly 
increased serum levels of inflammatory, pro-Th1 
(IL-12, p<0.05) and pro-Th17 cytokines (IL-1β, p<.0.05; 
IL-6, p<0.05) as well as IFN-γ (p<0.05) and IL-17 
(p<0.05) were found in WTGal-3-/-DCsPam3CSK4 mice 
(Figure 8E, left panel). Consistently, cellular make-up 
of the kidneys revealed significantly increased total 
number of IFN-γ and IL-17 producing neutrophils 
(Figure 8I-J, p<0.05) and CD4+ T cells (Figure 8K-L, 
p<0.01 for Th1 and p<0.05 for Th17 cells) in the 
CDDP-injured kidneys of WTGal-3-/-DCsPam3CSK4 mice, 
indicating that transfer of Gal-3-/-DCsPam3CSK4 
aggravated AKI in CDDP-treated WT recipients by 
enhancing IFN-γ and IL-17-driven inflammation. 
 
 
Figure 8. Transfer of WTDCsPam3CSK4 significantly attenuated CDDP-induced AKI in WT recipients by promoting expansion of immunosuppressive Tregs 
in IDO1/KYN-dependent manner. TLR-2-primed DCs, isolated from the kidneys of untreated WT and Gal‐3-/- mice (WTDCsPam3CSK4 and Gal‐3-/-DCsPam3CSK4), were 
intravenously injected (5×105cells/mouse) in CDDP-treated WT recipients (WTWTDCsPam3CSK4 and WTGal‐3-/-DCsPam3CSK4) two days prior CDDP administration (16 mg/kg body 
weight). IDO1 was inhibited in TLR-2-primed renal DCs (WTDCsPam3CSK4+1-MT) and Gal-3-/-DCs (Gal-3-/-DCsPam3CSK4+1-MT) by using 1-methyl tryptophan (1-MT; 2 mM). Transfer 
of WTDCsPam3CSK4 managed to attenuate CDDP-injured AKI and inflammation in CDDP-treated WT recipients, as evidenced by notably lower serum levels of urea (A), 
creatinine (B), decreased histological score (C), reduced extent of renal injury in the cortex of CDDP-injured kidneys (D), decreased serum levels of inflammatory, 
Th1/Th17-related cytokines and increased serum levels of immunosuppressive IL-10 and KYN (E), significantly higher presence of Tregs (F), and IL-10-producing neutrophils (G) 
and CD4+T cells (H), but notably decreased of IFN-γ (I) and IL-17-producing neutrophils (J) as well as IFN-γ (K) and IL-17-producing CD4+T cells (L). Transfer of 
WTDCsPam3CSK4+1-MT or Gal-3-/-DCsPam3CSK4 did not expand immunosuppressive Tregs (F), IL-10-producing neutrophils (G) and CD4+Tcells (H) in CDDP-injured kidneys, but 
promoted polarization of renal-infiltrating neutrophils (I-J) and CD4+T cells (K-L) towards IFN-γ-producing (I, K) and IL-17-producing cells (J, L), resulting in significant 
aggravation of CDDP-induced AKI in WT recipients (A-D). There was no significant difference between CDDP-treated WT recipients of Gal-3-/-DCsPam3CSK4+1-MT and 
Gal-3-/-DCsPam3CSK4 (A-L). Data from two individual experiments with 8 mice per group are shown as Mean ± SEM; *p<0.05, **p<0.01;***p<0.001. 






Figure 9. Transfer of WTDCsPam3CSK4 significantly attenuated CDDP-induced AKI in Gal-3-/- recipients by promoting expansion of immunosuppressive 
Tregs in IDO1/KYN-dependent manner. TLR-2-primed DCs, isolated from the kidneys of untreated WT and Gal‐3-/- mice (WTDCsPam3CSK4 and Gal‐3-/-DCsPam3CSK4), were 
intravenously injected (5×105cells/mouse) in CDDP-treated Gal-3-/- recipients (Gal-3-/-WTDCsPam3CSK4 and Gal-3-/-Gal‐3-/-DCsPam3CSK4) two days prior CDDP administration (16 mg/kg 
body weight). IDO1 was inhibited in TLR-2-primed renal DCs (WTDCsPam3CSK4+1-MT) and Gal-3-/-DCs (Gal-3-/-DCsPam3CSK4+1-MT) by using 1-methyl tryptophan (1-MT; 2 mM). 
Intravenous injection of WTDCsPam3CSK4 attenuated CDDP-injured AKI and inflammation in CDDP-treated Gal-3-/- recipients, as evidenced by notably lower serum levels of urea 
(A), creatinine (B), decreased histological score (C), reduced extent of renal injury in the cortex of CDDP-injured kidneys (D), decreased serum levels of inflammatory, 
Th1/Th17-related cytokines and increased serum levels of immunosuppressive IL-10 and KYN (E), significantly reduced total number of IFN-γ (F) and IL-17-producing neutrophils 
(G), IFN-γ-(H) and IL-17-producing CD4+T cells (J), but remarkably increased number of immunosuppressive Tregs (J), IL-10-producing neutrophils (K) and CD4+T cells (L). 
Transfer of WTDCsPam3CSK4+1-MT or Gal-3-/-DCsPam3CSK4 did not expand immunosuppressive Tregs (J), IL-10-producing neutrophils (K) and CD4+Tcells (L) in CDDP-injured 
kidneys, but promoted polarization of renal-infiltrating neutrophils (F-G) and CD4+T cells (H-I) towards IFN-γ-producing (F, H) and IL-17-producing cells (G, I), resulting in 
significant aggravation of CDDP-induced AKI in Gal-3-/- recipients (A-D). There was no significant difference between CDDP-treated WT recipients of Gal-3-/-DCsPam3CSK4+1-MT 
and Gal-3-/-DCsPam3CSK4 (A-L). Data from two individual experiments with 8 mice per group are shown as Mean ± SEM; *p<0.05, **p<0.01;***p<0.001. 
 
In similar manner as it was observed in 
CDDP-injured WT recipients (Figure 8; Figure S5), 
injection of Gal-3-/-DCsPam3CSK4 significantly 
aggravated renal failure in CDDP-treated Gal-3-/- 
recipients (Gal-3-/-Gal-3-/-DCsPam3CSK4) by promoting 
IFN-γ and IL-17-driven inflammation (Figure 9A-L; 
Figure S6). Importantly, transfer of WTDCsPam3CSK4 
completely attenuated AKI in CDDP-injured Gal-3-/- 
recipients (Gal-3-/-WTDCsPam3CSK4), confirming that 
expression of Gal-3 on DCs was crucially responsible 
for DCPam3CSK4-mediated amelioration of 
CDDP-induced nephrotoxicity (Figure 9). 





Significantly lower serum concentrations of urea and 
creatinine (p<0.05 for urea and p<0.01 for creatinine; 
Figure 9A-B) and notably reduced histological score 
were noticed in CDDP-treated Gal-3-/-WTDCsPam3CSK4 
mice (Figure 9C). CDDP-caused massive necrosis of 
proximal tubules, cast formation and erythrocyte 
congestion, observed in Gal-3-/- animals, were not 
seen in the kidneys of CDDP-treated 
Gal-3-/-WTDCsPam3CSK4s mice (Figure 9D). Biochemical 
and histological findings were accompanied by 
significantly lower serum levels of Th1 and 
Th17-related cytokines (p<0.05; Figure 9E, left panel) 
and remarkably reduced presence of IFN-γ and IL-17 
producing neutrophils (p<0.05; Figure 9F-G) and 
CD4+ T cells (p<0.05; Figure 9H-I) in the kidneys of 
CDDP-treated Gal-3-/-WTDCsPam3CSK4 mice. Transfer of 
WTDCsPam3CSK4 significantly elevated serum levels of 
nephroprotective IL-10 and KYN (p<0.01 for IL-10 
and p<0.001 for KYN; Figure 7E middle and right 
panels) that was followed by remarkable increase in 
total number of immunosuppressive CD4+FoxP3+ 
Tregs (p<0.01; Figure 9J), IL-10-producing neutrophils 
(p<0.05; Figure 9K) and CD4+ T cells (p<0.01 Figure 
9L) in the kidneys of CDDP-treated 
Gal-3-/-WTDCsPam3CSK4 mice. 
Importantly, 1-MT-induced inhibition of IDO1 
activity in TLR-2-primed WTDCs 
(WTDCsPam3CSK4+1-MT) completely abrogated their 
capacity to attenuate CDDP-induced AKI in 
CDDP-treated WT (WTWTDCsPam3CSK4+1-MT; Figure 8) 
and Gal-3-/-(Gal-3-/-WTDCsPam3CSK4+1-MT; Figure 9) 
recipients. Transfer of WTDCsPam3CSK4+1-MT failed to 
promote expansion of immunosuppressive 
CD4+FoxP3+Tregs (Figure 8J and Figure 9J) and to 
prevent their trans-differentiation in Th1 and Th17 
cells (Figure 8K-L and Figure 9H-I). Additionally, 
reduced presence of Tregs was accompanied with 
significantly lower number of IL-10-producing 
neutrophils (Figure 8H and Figure 9K) and increased 
number of IFN-γ (p<0.001; Figure 8I and Figure 9F) 
and IL-17 producing neutrophils (p<0.05; Figure 8J 
and p<0.001; Figure 9G), indicating that activation of 
IDO1/KYN pathway was crucially important for 
Gal-3-dependent immunosuppressive effects of renal 
DCsPam3CSK4 and for DCsPam3CSK4-induced expansion of 
Tregs.  
In order to determine whether Gal-3 and IDO1 
are members of the same TLR-2-initiated signaling 
pathway responsible for DCs-mediated attenuation of 
CDDP-induced AKI, we inhibited IDO1 activity in 
Gal-3 deficient TLR-2-primed DCs (Gal-3-/- 
DCsPam3CSK4+1-MT) and analyzed their nephroprotective 
and immunosuppressive effects in CDDP-treated WT 
(Figure 8) and Gal-3-/- recipients (Figure 9). There was 
no significant difference in serum levels of urea and 
creatinine (Figure 8A and Figure 9A), extent of renal 
injury (Figure 8C-D and Figure 9C-D), serum 
concentration of inflammatory and immunosup-
pressive cytokines (Figure 8E and Figure 9E), total 
number of renal-infiltrated IFN-γ and 
IL-17-producing neutrophils (Figure 8I-J and Figure 
9F-G), Th1 and Th17 lymphocytes (Figure 8K-L and 
Figure 9H-I) and IL-10-producing neutrophils and 
Tregs (Figure 8F-H and Figure 9J-L) between 
CDDP-treated WT and Gal-3-/- recipients of 
Gal-3-/-DCsPam3CSK4+1-MT and Gal-3-/-DCsPam3CSK4. Thus, 
inhibition of IDO1 activity did not significantly alter 
immunomodulatory properties of TLR-2-primed 
Gal-3-/-DCs, suggesting that Gal-3 and IDO1 are 
members of the same TLR-2-initiated signaling 
pathway which was responsible for nephroprotective 
and immunosuppressive effects of TLR-2-primed 
renal DCs in attenuation of CDDP-induced AKI. 
Expression of Gal-3 on TLR-2-primed DCs is 
crucially important for their capacity to 
enhance nephroprotective and 
immunosuppressive properties of Tregs 
It is well known that Tregs suppress 
CDDP-induced acute renal inflammation and that 
depletion of Tregs results in exacerbation of AKI [9]. 
In order to confirm crucial importance of Gal-3:TLR-2 
axis for DC-dependent enhancement of 
nephroprotective and immunosuppressive properties 
of Tregs, we intravenously injected non-primed Tregs, 
Tregs primed with WTDCPam3CSK4, 
WTDCPam3CSK4+Davanat or Gal-3-/- DCPam3CSK4 in 
Treg-depleted CDDP-treated WT mice (Figure 10; 
Figure S7). WTDCPam3CSK4 significantly enhanced 
capacity of Tregs for attenuation of CDDP-induced 
AKI and inflammation. Significantly lower serum 
levels of urea and creatinine (p<0.01; Figure 10A) and 
reduced histological score (p<0.01; Figure 10B) were 
observed in Treg-depleted CDDP-treated mice that 
received WTDCPam3CSK4-primed Tregs compared to 
the Treg-depleted CDDP-injured animals that 
received non-primed Tregs. Histological analysis 
revealed preserved architecture of renal tissue and 
paucity of renal-infiltrated inflammatory cells in the 
kidneys of Treg-depleted CDDP-treated mice that 
received WTDCPam3CSK4-primed Tregs (Figure 10B). 
Additionally, WTDCPam3CSK4 significantly enhanced 
capacity of Tregs to inhibit production of 
inflammatory cytokines (IFN-γ, IL-17, TNF-α) and to 
promote production of immunosuppressive IL-10 in 
renal-infiltrated neutrophils, as evidenced by 
significantly lower number of T-bet-expressing, 
IFN-γ-, IL-17- and TNF-α-producing neutrophils 
(p<0.01; Figure 10C-F) and remarkably higher number 
of IL-10-producing neutrophils (p<0.001; Figure 10G) 





in the kidneys of Treg-depleted CDDP-treated mice 
that received WTDCPam3CSK4-primed Tregs. 
Importantly, genetic deletion or pharmacological 
inhibition of Gal-3 remarkably attenuated capacity of 
TLR-2-primed DCs to enhance nephroprotective and 
immunosuppressive properties of Tregs, as evidenced 
by significantly higher serum concentrations of urea 
and creatinine (p<0.01; Figure 10A), more severe 
injury of proximal tubular epithelial cells and 
increased histological score (p<0.01; Figure 10B), 
significantly higher number of inflammatory 
neutrophils (p<0.05 for IL-17-producing and p<0.001 
for T-bet-expressing, IFN-γ- and TNF-α-producing 
CD45+Gr-1+cells; Figure 10C-F) and significantly 
reduced number of immunosuppressive, 
IL-10-producing neutrophils (p<0.01; Figure 10G) in 
the kidneys of Treg-depleted CDDP-treated mice that 
received Gal-3-/-DCPam3CSK4 or WTDCPam3CSK4+Davanat 
-primed Tregs compared to Treg-depleted CDDP- 




Figure 10. Expression of Gal-3 on TLR-2-primed DCs is crucially important for their capacity to enhance nephroprotective and immunosuppressive 
properties of Tregs. For the depletion of Tregs, anti-CD25 monoclonal antibody (250 μg/mouse) was intraperitoneally given to mice 3 days before CDDP administration (16 
mg/kg body weight). For transfer experiments non-primed Tregs, Tregs primed with WTDCPam3CSK4, WTDCPam3CSK4+Davanat or Gal-3-/- DCPam3CSK4 (1x106 Tregs/ mouse) were 
intravenously injected in CDDP-treated animals 18 h before induction of AKI. Significantly lower serum levels of urea and creatinine (A) and reduced histological score 
accompanied with attenuated renal injury, observed in the cortex of CDDP-injured kidneys (B) were observed in Treg-depleted CDDP-treated mice that received 
WTDCPam3CSK4-primed Tregs compared to the Treg-depleted CDDP-injured animals that received non-primed Tregs. There was significantly lower number of T-bet-expressing, 
IFN-γ-, IL-17- and TNF-α-producing neutrophils (C-F) and remarkably higher number of IL-10-producing neutrophils (G) in the kidneys of Treg-depleted CDDP-treated mice 
that received WTDCPam3CSK4-primed Tregs. Significantly higher serum concentrations of urea and creatinine (A), more severe injury of proximal tubular epithelial cells and 
increased histological score (B), significantly higher number of inflammatory neutrophils (C-F) and significantly reduced number of immunosuppressive, IL-10-producing 
neutrophils (G) in the kidneys of Treg-depleted CDDP-treated mice that received Gal-3-/-DCPam3CSK4 or WTDCPam3CSK4+Davanat -primed Tregs compared to Treg-depleted 
CDDP-treated mice that received WTDCPam3CSK4-primed Tregs. Individual data points with Mean, obtained in one experiment with 6 mice per group; *p<0.05, 
**p<0.01,***p<0.001. 





Depletion of Tregs diminished 
Gal-3-dependent capacity of TLR-2-primed 
renal DCs to suppress IFN-γ and IL-17 driven 
inflammation in CDDP-injured kidneys 
In order to determine the importance of Tregs for 
Gal-3-dependent nephroprotective and 
immunosuppressive function of TLR-2-primed renal 
DCs, we analyzed the effects of CY or anti-CD25 
antibody-induced depletion of Tregs in CDDP-treated 
WTWTDCsPam3CSK4 and Gal-3-/-WTDCsPam3CSK4mice (Figure 
11; Figure S8). Depletion of Tregs completely 
abrogated Gal-3-dependent nephroprotective and 
immunosuppressive effects of WTDCsPam3CSK4 (Figure 
11A-D). Significantly increased serum levels of urea, 
creatinine (p<0.05; Figure 11A-B), histological score 
(Figure 11C) and massive tubular injury (Figure 11D) 
were observed in CY+CDDP- and 
anti-CD25+CDDP-treated WTWTDCsPam3CSK4s and 
Gal-3-/-WTDCsPam3CSK4smice. Significantly elevated 
serum concentrations of IFN-γ and IL-17 (p<0.05; 
Figure 11E) and remarkably higher presence of IFN-γ 
and IL-17 producing neutrophils (Figure 11F-G, 
p<0.05) and CD4+ T cells (Figure 11H-I, p<0.01 for 
Th1 and p<0.05 for Th17 cells) were observed in the 
kidneys of CY+CDDP- and anti-CD25+CDDP-treated 
WTWTDCsPam3CSK4 and Gal-3-/-WTDCsPam3CSK4mice, 
indicating that depletion of Tregs diminished 
Gal-3-dependent capacity of TLR-2-primed DCs to 
suppress IFN-γ and IL-17 driven inflammation in 
AKI.  
Discussion 
Renal DCs represent specific sub-population of 
resident kidney immune cells which acquire distinct 
phenotypic and functional characteristics depending 
on the intrarenal inflammatory conditions, having 
pro-inflammatory and pathogenic role in T 
cell-mediated glomerulonephritis and lupus 
nephritis, while playing immunosuppressive and 
nephroprotective role in CDDP-induced AKI [4]. 
Under the influence of DAMPs and alarmins, which 
are released from CDDP-injured PTECs, renal DCs 
acquire tolerogenic phenotype and immunosup-
pressive characteristics which enable them to elicit 
strong anti-inflammatory and reparative response in 
the CDDP-injured kidneys [4]. Accordingly, depletion 
of renal DCs significantly aggravated tubular injury 
and renal dysfunction and considerably reduced 
survival of CDDP-treated mice [5]. 
The role of Gal-3 for migration and 
antigen-presenting function of bone marrow-derived 
DCs has already been described by us and others 
[12-13, 18-19, 42, 58-59]. Interestingly, renal DCs and 
bone marrow-derived DCs significantly differ in their 
capacity to produce immunosuppressive cytokines 
which are responsible for DC-dependent attenuation 
of CDDP-caused renal injury and inflammation [5-6, 
60]. In line with these findings, we provide here the 
first evidence on the importance of Gal-3 for 
immunosuppressive effects of renal DCs in alleviation 
of CDDP-caused renal injury and inflammation. 
Genetic deletion as well as pharmacological inhibition 
of Gal-3 significantly impaired capacity of renal DCs 
to induce TLR-2:IDO-1-dependent expansion of 
renal-infiltrating Tregs and to initiate reparative 
response in CDDP-injured kidneys (Figure 4-7). 
Accordingly, remarkably reduced total number of 
immunosuppressive, IL-10 producing neutrophils 
(Figure 2E), M2 macrophages (Figure 2I) and Tregs 
(Figure 3G), but increased presence of inflammatory 
M1 macrophages (Figure 2H), IFN-γ or 
IL-17-producing neutrophils (Figure 2B-C) and CD4+ 
T cells (Figure 3B-E) was noticed in CDDP-injured 
kidneys of Gal-3-/- animals resulting in significant 
aggravation of renal injury and inflammation. 
Gal-3, as a constitutive member of AGE receptor 
complex, is involved in AGEs removal from 
circulation and, accordingly, its deficiency results in 
the aggravation of AGE-induced glomerular injury 
[27-28]. An enhanced AGEs formation in 
CDDP-injured kidneys and increased activation of 
AGE receptors on renal DCs promote generation of 
tolerogenic and immunosuppressive phenotype in 
renal DCs resulting in DC-mediated attenuation of 
CDDP-induced AKI [29]. Having in mind that 
aggravated AKI and impaired uptake of AGEs, 
observed in CDDP-treated Gal-3-/- kidneys (Figure 
1A-D) corresponded with reduced 
immunosuppressive and nephroprotective function of 
Gal-3-/-DCs (Figure 6-7), we assume that Gal-3 
deficiency resulted in unstable expression of AGE 
receptor complex and significantly impeded AGE 
receptor-dependent generation of tolerogenic 
phenotype in renal DCs.  
Since membranous Gal-3 lacks intracellular 
peptide sequence with enzymatic activity, it has to 
associate with other membrane-bound receptors in 
order to transduce signals from activated AGE 
receptor [28]. CDDP treatment up-regulated 
expression of Gal-3 in injured kidneys (Figure 1E). An 
increased expression of Gal-3 was accompanied with 
enhanced expression of TLR-2 (Figure 1F), while Gal-3 
deficiency attenuated CDDP-caused up-regulation of 
TLR-2 (Figure 1E-F). It is well known that activation of 
TLR-2 protects against CDDP-induced nephrotoxicity 
by inducing autophagy which delays apoptosis of 
PTECs [3]. Accordingly, Gal-3 deficiency and reduced 
expression of TLR-2 increased susceptibility to 
CDDP-induced apoptosis (Figure 1D), while 





administration of rGal-3 significantly attenuated 
CDDP-induced AKI in Gal-3-/- mice by preventing 
Bax and caspase-3-dependent apoptosis (Figure 
2E-H). CDDP induces apoptosis of PTECs through the 
activation of the intrinsic mitochondrial pathway 
driven by Bax and caspase-3 [61]. Gal-3, after 
exposure to apoptotic stimuli, translocates from the 
cytosol or nucleus to the mitochondria and attenuates 
apoptosis by inhibiting Bax oligomerization [62-63]. 
Most of Gal-3 inhibitors (Davanat, modified citrus 
pectin (MCP), G3-C12) bind to the Gal-3 at the 
carbohydrate recognition domain (CRD) and prevent 
Gal-3:Bax interaction [64]. Accordingly, significantly 
increased Bax and caspase-3-dependent apoptosis and 
aggravated AKI were observed in 
CDDP+Davanat-treated animals (Figure 2A-D). 
However, it should be noted that capacity of Gal-3 
inhibitors for modulation of CDDP-induced apoptosis 
probably depends on their selectivity and should be 
further investigated since opposite, pro- and 
anti-apoptotic effects were recently observed in 
MCP-treated cells [25, 63].  
 
 
Figure 11. Depletion of Tregs completely diminished Gal-3-dependent capacity of TLR-primed renal DCs to suppress IFN-γ and IL-17 driven 
inflammation in CDDP-injured kidneys. For the depletion of Tregs, CDDP-treated WTWTDCPam3CSK4 and Gal-3-/-WTDCPam3CSK4 mice received either cyclophosphamide (CY; 
10 mg/kg) 3 days before CDDP administration (16 mg/kg body weight) or anti-CD25 (P61) monoclonal antibody (250 μg/mouse). Significantly elevated serum levels of urea (A) 
and creatinine (B), increased histological score (C), more severe tubular epithelial cell injury (D), elevated serum levels of IFN-γ and IL-17 (E), increased presence of IFN-γ- and 
IL-17-producing neutrophils (F-G), and IFN-γ- and IL-17-producing CD4+T cells (H-I) were noticed in the kidneys of CY+CDDP- and anti-CD25+CDDP-treated WT and Gal-3-/- 
recipients of WTDCsPam3CSK4 compared to CDDP-treated WTWTDCsPam3CSK4 and Gal-3-/-WTDCsPam3CSK4 that were not depleted from Tregs (J). Data from two individual experiments 
with 8 mice per group are shown as Mean ± SEM; *p<0.05, **p<0.01;***p<0.001. 






Figure 12. Expression of Gal-3 in renal DCs is necessary for optimal TLR-2-dependent activation of IDO1/KYN pathway and for consequent expansion of 
renal-infiltrating Tregs. Gal-3, expressed on renal DCs, serves as receptor for AGEs which promotes TLR-2-dependent activation of IDO1/KYN pathway and protects 
against CDDP-caused AKI by inducing expansion of Tregs which, in turn, promote generation of immunosuppressive, IL-10-producing phenotype in renal-infiltrated neutrophils 
and prevent inflammation driven by IFN-γ- and IL-17-producing neutrophils, Th1 and Th17 cells (upper panel). Gal-3 deficiency resulted in reduced uptake of AGEs, attenuated 
activation of TLR-2-dependent IDO1/KYN pathway in renal DCs, decreased production of KYN, reduced presence of immunosuppressive Tregs and enhanced expansion of 
inflammatory IFN-γ- and IL-17-producing neutrophils, Th1 and Th17 cells in the kidneys, resulting in significant aggravation of CDDP-induced AKI (lower panel). 
 
While Harazono and colleagues demonstrated 
that MCP suppressed Gal:Bax heterodimerization and 
promoted apoptosis [63], Li and co-workers showed 
that MCP attenuated CDDP-induced AKI by 
suppressing protein kinase C-α (PKC-α)-driven 
apoptosis [25]. These opposite findings may be 
explained by the fact that MCP, in similar manner as 
PKC-α, interferes with multiple intracellular 
pathways and, therefore, could acts as pro- or 
anti-apoptotic agent, depending upon cell type or 
tissue microenvironment [65-68]. Furthermore, 
different effects of Gal-3 inhibition in modulation of 
CDDP-induced apoptosis could be due to the 
different doses of CDDP (16mg/kg vs. 20mgkg body 
weight) which were used in our and in study 
conducted by Li and colleagues [25]. There is evidence 
that different doses of CDDP may differentially affect 
development and progression of AKI in mice and in 
some cases may even hamper the comparison and 
interpretation of the results [69].  
Several lines of evidence demonstrated that 
Gal-3 associates with TLR-2 on the cell membrane of 
macrophages and DCs in order to modulate 
macrophage or DC-driven immune response [52-53]. 
The extent of AKI was not different between 
CDDP-treated WT recipients of TLR-2-primed WT 
and Gal-3-/-macrophages (Figure S1), suggesting that 
genetic deletion of Gal-3 did not affect 
immunomodulatory capacity of TLR-2-activated 
macrophages. On the contrary, strong positive 
correlation between Gal-3 and TLR-2-expressing renal 
DCs (Figure 7A), high percentage of Gal-3-expressing 
cells in the population of TLR-2-expressing renal DCs 
(Figure 7B) and significantly reduced presence of 
TLR-2-expressing DCs in injured kidneys of 
CDDP-treated Gal-3-/-mice (Figure 7C) indicated the 
important role of Gal-3 for TLR-2-dependent 
activation of renal DCs.  
It is well known that expression of TLR-2 is 
needed for optimal AGE receptor-dependent 
generation of immunosuppressive phenotype in renal 
DCs [2-3, 70-71]. DAMPs, released from 
CDDP-injured PTECs, bind to TLR-2 which interacts 
with activated AGE receptors to induce development 
of immature, tolerogenic phenotype in DCs [2, 70-72]. 
In line with these findings, activation of TLR-2 
down-regulates expression of co-stimulatory (CD80 
and CD86) and MHC-class II molecules on DCs, 
reduces production of Th1 (IL-12) and Th17-related 
(IL-1, IL-6, IL-23, TGF-β) cytokines and attenuates 
capacity of DCs to induce differentiation of naïve 
CD4+ T cells in effector IFN-γ-producing Th1 and 
IL-17-producing Th17 cells [2, 70-72]. In line with 
these findings, significantly reduced number of TLR-2 





expressing DCs, observed in CDDP-injured kidneys 
of Gal-3-/- mice (Figure 7C), corresponded to the 
higher number of CD80, CD86 and MHC class 
II-expressing (Figure 6D-F) and IL-12 or 
IL23-producing DCs (Figure 6G-H). Accordingly, 
significantly elevated serum levels of Th1 and 
Th17-related cytokines (Figure 1H), and remarkably 
higher number of renal-infiltrated IFN-γ-producing, 
T-bet-expressing Th1 cells (Figure 4B-C) and 
IL-17-producing, RORγT-expressing Th17 cells 
(Figure 4D-E) were noticed in CDDP-treated Gal-3-/- 
mice, suggesting the important role of Gal-3 for 
TLR-2-dependent modulation of DC:T cell cross-talk 
in CDDP-injured kidneys. 
It is well known that activation of TLR-2 
promotes production of anti-inflammatory IL-10 in 
DCs [73] which plays an important role in 
DC-dependent attenuation of CDDP-induced AKI [5]. 
In line with these findings, significantly lower number 
of TLR-2 expressing DCs, observed in the kidneys of 
CDDP-treated Gal-3 deficient mice (Figure 7B), was 
accompanied by significantly lower serum levels of 
IL-10 (Figure 1I) and notably reduced number of 
IL-10-producing renal DCs (Figure 6B), suggesting 
that Gal-3 was necessary for optimal TLR-2 induced 
production of immunosuppressive IL-10 in renal DCs. 
Accordingly, adoptive transfer of WTDCsPam3CSK4 
significantly increased serum levels of IL-10 (Figure 
8E and Figure 9E) and efficiently attenuated AKI in 
CDDP-treated WT and Gal-3-/- mice (Figure 8A-D and 
Figure 9A-D). This phenomenon was not observed in 
CDDP-injured WT and Gal-3-/- recipients that 
received Gal-3-/-DCsPam3CSK4 (Figure 8-9), indicating 
crucial importance of Gal-3 for optimal 
TLR-2-induced production of anti-inflammatory IL-10 
in renal DCs.  
In addition to IL-10, TLR-2-priming also triggers 
expression of immunosuppressive IDO1 resulting in 
the generation of tolerogenic phenotype in DCs [74]. 
In line with these findings, intracellular staining 
revealed that most of Gal-3+TLR-2+ renal DCs 
expressed immunosuppressive IDO1 (Figure 7C) and 
that majority of TLR-2+Gal-3+IDO1+ renal DCs were 
anti-inflammatory, IL-10-producing cells (Figure 7F), 
suggesting that Gal-3:TLR-2 cross-talk was involved 
in generation of immunosuppressive and tolerogenic 
phenotype in renal DCs. TLR-2 priming results in 
increased activation of Phosphoinositide 3-kinase 
(PI3K)/Akt signaling pathway in DCs leading to the 
enhanced production of IL-10 [75]. Activated TLR-2 
recruits PI3K which converts phosphatidylinositol 
4,5-bisphosphate (PIP2) to phosphatidylinositol 
3,4,5-trisphosphate (PIP3). PIP3 enables activation of 
Akt. Activated Akt, on turn, inactivates Glycogen 
Synthase Kinase 3 (GSK3) and promotes nuclear 
accumulation of cAMP Response Element-Binding 
Protein (CREB) which displaces NF-κB p65 from the 
co-activator of transcription (CREB binding protein 
(CBP)). Accordingly, enhanced transcriptional activity 
of CREB leads to the reduced transcriptional activity 
of NF-κB p65 and results in increased IL-10 
production and decreased production of 
pro-inflammatory cytokines in TLR-2-primed DCs 
[75]. Gal-3 stimulates activation of PI3K/Akt 
signaling pathway in macrophages and promotes 
their conversion in M2 immunosuppressive 
phenotype in PI3K/Akt-dependent manner [76]. 
Although we did formally prove TLR-2:Gal-3 
interaction, it is clear that TLR-2 and Gal-3 play in 
concert. Accordingly, we assume that 
Gal-3:TLR-2-dependent induction of tolerogenic 
phenotype in renal DCs was a consequence of 
increased PI3K/Akt activity.  
TLR-2-induced increased expression of IDO1 
results in increased production of 
immunosuppressive KYN in bone-marrow derived 
DCs [8, 73, 77]. In line with these findings, we noticed 
that activation of TLR-2 significantly enhanced 
production of KYN in renal DCs (Figure 7E). 
Importantly, Gal-3 was crucially important for 
optimal TLR-2-dependent activation of IDO1/KYN 
pathway in renal DCs. Genetic deletion or 
pharmacological inhibition of Gal-3 remarkably 
reduced capacity of renal DCs to secrete KYN upon 
TLR-2 activation (Figure 7E). Significantly lower 
number of TLR-2 expressing DCs, found in the 
kidneys of CDDP-treated Gal-3 deficient mice (Figure 
7C), was accompanied by significantly lower serum 
levels of KYN (Figure 1J) and notably reduced 
number of IDO1-expressing DCs in CDDP-injured 
kidneys (Figure 6C).  
DCs, in IDO1/KYN-dependent manner, 
promotes activation of Treg lineage-defining 
transcription factor (forkhead box P3-FoxP3) in 
CD4+T cells enabling generation of 
immunosuppressive CD4+FoxP3+Tregs in inflamed 
and injured tissues [8]. In line with these findings, we 
showed that Gal-3 and IDO1 are members of the same 
TLR-2-initiated signaling pathway which was 
responsible for DCs:Tregs cross-talk in CDDP-injured 
kidneys. Gal-3-dependent nephroprotective effects of 
TLR-2-activated renal DCs has been relied on the 
IDO1-induced expansion of renal-infiltrating Tregs 
since either inhibition of IDO1 activity in 
TLR-2-primed renal DCs (Figure 8-9) or depletion of 
Tregs (Figure 11) completely diminished 
DCPam3CSK4-mediated attenuation of CDDP-induced 
AKI.  
Tolerogenic DCs, in IDO1/KYN-dependent 
manner, prevent transdifferention of resting Tregs in 





effector Th1 or Th17 cells [77]. During TCR-mediated 
activation, signals via the protein kinase B (PKB/Akt) 
and mammalian target of rapamycin (mTOR) cause 
reprogramming of Tregs into inflammatory IFN-γ and 
IL-17 producing CD4+T cells [77]. Tolerogenic DCs, in 
IDO1/KYN-dependent manner, induce activation of 
general control nonderepressible 2 (GCN2) kinase 
which inhibits Akt/mTOR signaling in Tregs 
preventing their transdifferention in Th1/Th17 cells 
[77]. Expression of Gal-3 was necessary for optimal 
activation of IDO1/KYN pathway in renal 
DCsPam3CSK4 (Figure 7E) and for consequent 
IDO1/KYN-dependent maintenance of 
immunosuppressive function of Tregs by DCsPam3CSK4 
(Figure 7H-J). Decreased expression and production 
of anti-inflammatory IL-10 and increased expression 
and production of inflammatory IFN-γ and IL-17 
were noticed in Tregs which had been cultured with 
Gal-3-/-DCsPam3CSK4 or WT DCPam3CSK4+Davanat compared 
to Tregs that were cultured with WTDCsPam3CSK4 
(Figure 7H-J). Accordingly, adoptive transfer of 
WTDCsPam3CSK4, but not transfer of 
Gal-3-/-DCsPam3CSK4, significantly increased total 
number of immunosuppressive, IL-10-producing 
Tregs and remarkably reduced presence of 
inflammatory, IFN-γ and IL-17-producing CD4+T 
cells in the kidneys of CDDP-treated WT and Gal-3-/- 
recipients (Figure 8-9).  
Adoptive transfer of Tregs alleviated 
CDDP-induced nephrotoxicity [9], indicating 
Tregs-based therapy as a promising approach for 
amelioration of acute renal failure and inflammation 
[10]. Although Gal-3 is constitutively expressed on 
Tregs, Gal-3 deficiency did not alter migratory, 
nephroprotective and immunosuppressive capacity of 
Tregs (Figure 5). Nevertheless, expression of Gal-3 on 
TLR-2-primed DCs was crucially responsible for their 
capacity to enhance nephroprotective and 
immunosuppressive properties of Tregs (Figure 10). 
Tregs, activated by WTDCsPam3CSK4 more efficiently 
attenuated CDDP-induced nephrotoxicity than 
WTDCPam3CSK4-non-primed Tregs. Importantly, 
genetic deletion or pharmacological inhibition of 
Gal-3 completely diminished capacity of 
WTDCsPam3CSK4 to enhance nephroprotective 
properties of Tregs, indicating crucially important 
role of Gal-3 for the crosstalk of TLR-2-primed renal 
DCs and Tregs in Tregs-based attenuation of 
CDDP-induced AKI (Figure 9).  
It is well known that Tregs may induce 
production of immunosuppressive cytokines in 
neutrophils [78] leading to the attenuation of AKI [79]. 
In line with these findings, significantly lower number 
of renal-infiltrated TLR-2 expressing DCs (Figure 7C) 
and consequently reduced presence of Tregs (Figure 
4G) were accompanied with reduced presence of 
IL-10-producing neutrophils in injured kidneys of 
CDDP-treated Gal-3-/- mice (Figure 3E). Additionally, 
Tregs, which had been cultured with WTDCsPam3CSK4 
promoted expression of IL-10 and suppressed 
expression of inflammatory cytokines (IFN-γ and 
IL-17) in neutrophils (Figure 7F and Figure 10D-E), 
while Tregs generated in the presence of 
Gal-3-/-DCsPam3CSK4or WT DCsPam3CSK4+Davanat were not 
able to generate immunosuppressive phenotype in 
activated neutrophils (Figure 7F). Accordingly, in 
contrast to WTDCsPam3CSK4, adoptive transfer of 
Gal-3-/-DCsPam3CSK4 did not result in expansion of 
renal-infiltrating Tregs and IL-10 producing 
neutrophils in the kidneys of CDDP-treated WT and 
Gal-3-/- recipients (Figure 8-9), indicating the 
important role of Gal-3 for TLR-2-dependent 
DC-driven regulation of Tregs:neutrophils crosstalk 
in injured kidneys. 
In conclusion, we propose that expression of 
Gal-3 in renal DCs is crucially important for their 
protective effects in CDDP-induced AKI. The main 
mechanism by which Gal-3 regulates 
immunosuppressive capacity of renal DCs is relied on 
the TLR-2-dependent activation of IDO1/KYN 
pathway and consequent expansion of 
IL-10-producing renal-infiltrated Tregs which 
suppress neutrophil-, Th1- and Th17 cell-driven 
inflammation in CDDP-injured kidneys (Figure 12). 
Activation of Gal-3:TLR-2:IDO1 pathway in renal DCs 
should be further explored as new therapeutic 
approach for DC-based immunosuppression of 
inflammatory renal diseases. 
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